English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The treatment of patients with multiple sclerosis (MS) with immunomodulatory drugs, and more recently, with immunosuppressive drugs, have modified the natural history of the disease in the last years. The conclusions and recommendations elaborated by several authors based upon multicenter studies make us review and update concepts, proposing modifications to government institutions in order to improve the assistance to MS patients, the main purpose of this work. Herein, the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology judged important to update the recommendations concerning MS diagnosis criteria, classification of progression patterns, foundation of reference centers and the use of immunomodulatory drugs.

Diretrizes para o tratamento da esclerosa mútipla com drogas imunomoduladoras